Reneo Pharmaceuticals Secures $50 Million Series A Financing to Advance Innovative Therapies for Inherited Mitochondrial Diseases

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on May 20, U.S. local time, biopharmaceutical company Reneo Pharmaceuticals completed a $50 million Series A financing round. The proceeds from this round will be used to support the company’s development of biologic drugs for the treatment of mitochondrial diseases caused by genetic defects.

It is reported that this round of financing was led by New Enterprise Associates, with participation from Lundbeckfonden Ventures, Pappas Capital, and RiverVest.

Headquartered in California, USA, Reneo Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for patients with inherited mitochondrial diseases. The company’s current clinical research programs primarily target several inherited metabolic disorders, including primary mitochondrial myopathy and fatty acid oxidation disorders.

Primary Mitochondrial Myopathies (PMMs) are a rare disorder caused by mitochondrial gene mutations. Symptoms include muscle pain, weakness, cramps, and atrophy, accompanied by exercise intolerance, dysphagia, and severe muscle tissue damage such as rhabdomyolysis. These symptoms can range from mild muscle fatigue to significant impairment of normal physical activities. The disease can occur at any age, with younger patients typically experiencing more severe symptoms.

Fatty Acid Oxidation Disorders (FAODs) are rare, potentially life-threatening inherited metabolic disorders that impair the body’s ability to utilize dietary fats. Numerous enzymes and transporters play critical roles in converting dietary fats into essential energy; however, in patients with FAODs, genetic defects significantly compromise the biological activity of these enzymes and proteins.

Long-chain fatty acid oxidation disorders typically present with symptoms in infancy or early childhood, which may include feeding difficulties, lack of energy (lethargy), hypoglycemia, and decreased muscle tone. Adults with mild forms of the disease may experience hypoglycemia, fatigue, myalgia, rhabdomyolysis, and loss of sensation in the arms and legs.

REN 001 is an investigational, clinical-stage compound known to modulate numerous genes that influence mitochondrial activity. Reneo Pharmaceuticals is developing this compound with the aim of improving cellular energy metabolism by enhancing mitochondrial function and increasing mitochondrial biogenesis, thereby treating mitochondrial dysfunction and assisting healthcare teams in managing conditions such as primary mitochondrial myopathy and fatty acid oxidation disorders.

New Enterprise Associates, founded in 1977 and headquartered in California, USA, is a global venture capital firm that focuses on investing across the early, growth, and late stages of company development. It helps entrepreneurs build transformative businesses across multiple industries and regions, with over $19 billion in committed capital to date.

Lundbeckfonden Ventures is a Danish venture capital firm focused on investing in the life sciences sector. Established in 2009 and affiliated with the Lundbeck Foundation, it invests up to €50 million annually and has completed 49 investments to date.

Pappas Capital, founded in 1994 and headquartered in North Carolina, USA, is a venture capital firm that focuses on investing in the early and late-stage development of startups in the fields of biotechnology, biopharmaceuticals, drug delivery, and medical devices. Its primary investment geographic scope includes the United States and Canada. To date, the firm has completed 10 investments.

RiverVest, founded in 2000 and headquartered in Missouri, USA, is a venture capital firm primarily investing in early-stage life sciences companies. RiverVest’s investment team identifies, discovers, and actively nurtures promising life sciences companies in the medical device and biopharmaceutical industries, helping entrepreneurs drive the early development of their startups.

(Compiled by Liu Yujing)